Prime Medicine
Ken Leslie has a diverse work experience spanning over two decades. Ken is currently working as the VP of Business Development at Prime Medicine, Inc. since March 2022. Prior to this, they held the position of Senior Director of Business Development - External Innovation at Vertex Pharmaceuticals from September 2018 to March 2022. Ken also worked as the Director of Strategy and Corporate Development at Pacira Pharmaceuticals, Inc. from August 2016 to September 2018. Ken started their career as a Research Technician at the Gene Therapy Core Facility at Cornell University Medical School in August 1999 and later served as a Senior Research Associate at the Memorial Sloan-Kettering Cancer Center from June 2001 to July 2008. From there, they transitioned to finance and worked as a Specialty Pharmaceuticals Equity Research Summer Research Associate at UBS Investment Bank in July 2009. Ken then held the role of Healthcare Analyst at Soros Fund Management from October 2009 to September 2012. Following this, they worked as an Analyst at Suffolk Capital Management from April 2013 to November 2014 before becoming a Healthcare Therapeutics Analyst at Goldwater Asset Management from November 2014 to April 2016. Ken Leslie's career trajectory showcases their expertise in research, strategy, corporate development, and business development within the pharmaceutical industry.
Ken Leslie obtained a BA degree in Molecular Biology, Neuroscience, and Pre-Med from an unspecified school, which they attended from 1995 to 1999. Subsequently, from 2008 to 2010, they pursued an MBA degree with a focus on Finance, although the specific institution is not mentioned.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.